IRulya Therapeutics, Inc. (IRLA)
39.88
-0.06
(-0.15%)
USD |
NASDAQ |
Nov 20, 16:00
39.93
+0.05
(+0.13%)
After-Hours: 20:00
IRulya Therapeutics Research and Development Expense (TTM) : 30.76M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 30.76M |
| June 30, 2026 | 32.99M |
| March 31, 2026 | 34.08M |
| December 31, 2025 | 35.38M |
| September 30, 2025 | 28.61M |
| June 30, 2025 | 25.44M |
| March 31, 2025 | 23.03M |
| December 31, 2024 | 18.39M |
| September 30, 2024 | 16.00M |
| June 30, 2024 | 12.51M |
| March 31, 2024 | 9.72M |
| December 31, 2023 | 9.448M |
| September 30, 2023 | 8.782M |
| June 30, 2023 | 9.802M |
| March 31, 2023 | 15.65M |
| Date | Value |
|---|---|
| December 31, 2022 | 24.29M |
| September 30, 2022 | 36.73M |
| June 30, 2022 | 48.32M |
| March 31, 2022 | 55.84M |
| December 31, 2021 | 60.79M |
| September 30, 2021 | 61.44M |
| June 30, 2021 | 64.38M |
| March 31, 2021 | 63.75M |
| December 31, 2020 | 61.31M |
| September 30, 2020 | 55.48M |
| June 30, 2020 | 46.75M |
| March 31, 2020 | 39.77M |
| December 31, 2019 | 30.21M |
| September 30, 2019 | 22.47M |
| June 30, 2019 | 16.63M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Korsana Biosciences, Inc. | 43.39M |
| PepGen Inc. | 52.70M |
| Q32 Bio, Inc. | 15.94M |
| Bridgebio Oncology Therapeutics, Inc. | 156.69M |
| Oncolytics Biotech, Inc. | 13.18M |